Zobrazeno 1 - 10 of 25 pro vyhledávání: '"Pauline VAFLARD"'
1
Akademický článek
Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program
Autor: Alexandre de Moura, Perrine Vuagnat, Benjamin Renouf, Jean-Yves Pierga, Delphine Loirat, Pauline Vaflard, Charline Lafayolle de la Bruyère, Natacha Chaumard-Billotey, Nawale Hajjaji, Sylvain Ladoire, Sandrine Dabakuyo, Anne Patsouris, Jean Sébastien Frenel, Vincent Nicolai, Marie Alexandre, Nadine Dohollou, Julien Grenier, Heloïse Bourien, François-Clément Bidard
Publikováno v: Scientific Reports, Vol 13, Iss 1, Pp 1-7 (2023)
Abstract Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab
Externí odkaz: https://doaj.org/article/32a11dfa386a4c37a6ba7f6ce998b444
Zobrazit plný text záznamu
2
Akademický článek
DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
Autor: Stefano Kim, Véronique Vendrely, Angélique Saint, Thierry André, Pauline Vaflard, Emmanuelle Samalin, Simon Pernot, Oliver Bouché, Mustapha Zubir, Jérôme Desrame, Christelle de la Fouchardière, Denis Smith, François Ghiringhelli, Angélique Vienot, Marion Jacquin, Elodie Klajer, Thierry Nguyen, Éric François, Julien Taieb, Karine Le Malicot, Dewi Vernerey, Aurélia Meurisse, Christophe Borg
Publikováno v: Experimental Hematology & Oncology, Vol 12, Iss 1, Pp 1-5 (2023)
Abstract Triplet DCF (docetaxel, cisplatin and 5-flurouracil) and doublet CP/CF (carboplatin and paclitaxel/cisplatin and 5-fluorouracil) regimens were prospectively evaluated in advanced squamous anal cell carcinoma (SCCA), and validated as standard
Externí odkaz: https://doaj.org/article/e56120f3ba0e48b2bc81859d07428c3b
Zobrazit plný text záznamu
3
Abstract P3-06-09: Real-world toxicity of pembrolizumab-based neoadjuvant regimen in patients with early triple negative breast cancer
Autor: Delphine Loirat, Emilie ARNAUD, Khaoula ALAOUI, Pauline VAFLARD, Sinen KORBI, Dalila MEZIANI, Lucie THIBAULT, Romain-Pacome DESMARIS, Jean-Guillaume FERON, Jean-Yves Pierga, Francois-Clement Bidard, Paul COTTU
Publikováno v: Cancer Research. 83:P3-06
Background Pembrolizumab (pembro, anti-PD-1 antibody) combined to chemotherapy (CT) in neoadjuvant/adjuvant setting has demonstrated its efficacy for early triple negative breast cancer (eTNBC). Pembro obtained FDA marketing authorization on July 26,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48c9b4b6a27e2ec783bb317d2994007e
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-09
Zobrazit plný text záznamu
9
Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies
Autor: Toulsie Ramtohul, Clara Tescher, Pauline Vaflard, Joanna Cyrta, Noémie Girard, Caroline Malhaire, Anne Tardivon
Publikováno v: Radiology. 305(3)
Background Ultrafast dynamic contrast-enhanced (DCE) MRI parameters are associated with breast cancer aggressiveness. However, the role of these parameters as predictive biomarkers for pathologic response after neoadjuvant chemotherapy (NAC) has been
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1161d1a92446435724421ffe9734096e
https://pubmed.ncbi.nlm.nih.gov/35880985
Zobrazit plný text záznamu
10
Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials
Autor: Francesco Ricci, Maud Kamal, Marie-Paule Sablin, Christophe Le Tourneau, Aurélien Latouche, Delphine Loirat, Charlotte Lecerf, Pauline Vaflard, Claire Morel, Xavier Paoletti, Ségolène Hescot, Vincent Servois, Roman Rouzier, Elvire Pons-Tostivint
Publikováno v: JCO precision oncology. 3
PURPOSE Immune checkpoint inhibitors (ICIs) have been demonstrated to improve overall survival (OS) in several tumor types. Durable responses have been reported with these agents in patients with melanoma and lung cancer. We aimed to quantify the pro
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdef10d5d6479ec1a3a9e88a60bcd15e
https://pubmed.ncbi.nlm.nih.gov/35100670
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje